Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile of the Oral Antiplatelet Agent Ticagrelor
Author:
- 1 May 2012
- journal article
- review article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 51 (5) , 305-318
Abstract
Acute coronary syndromes (ACS) remain life-threatening disorders associated with high morbidity and mortality, despite advances in treatment over the last decade. Adenosine diphosphate-induced...Keywords
This publication has 61 references indexed in Scilit:
- Lack of significant food effect on the pharmacokinetics of ticagrelor in healthy volunteersJournal of Clinical Pharmacy and Therapeutics, 2011
- Effect of ticagrelor on the pharmacokinetics of ethinyl oestradiol and levonorgestrel in healthy volunteersCurrent Medical Research and Opinion, 2011
- Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trialThe Lancet, 2010
- Absorption, Distribution, Metabolism, and Excretion of Ticagrelor in Healthy SubjectsDrug Metabolism and Disposition, 2010
- Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteersBritish Journal of Clinical Pharmacology, 2010
- Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor AntagonistCardiovascular Therapeutics, 2009
- The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculatureInternational Journal of Cardiology, 2009
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- LETTER TO THE EDITOR: P2Y1 gene polymorphism and ADP-induced platelet responseJournal of Thrombosis and Haemostasis, 2005
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionJACC, 2004